Cargando…

A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study

Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist, blocks the effect of intranasally administered vasopressin on brain processing of angry Ekman faces. An interaction of intranasal and oral drug was predicted in the amygdala. Methods: Twenty-nine healthy male subjects re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Royce J., Coccaro, Emil F., Cremers, Henk, McCarron, Rosemary, Lu, Shi-Fang, Brownstein, Michael J., Simon, Neal G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859978/
https://www.ncbi.nlm.nih.gov/pubmed/24376401
http://dx.doi.org/10.3389/fnsys.2013.00100
_version_ 1782295481968230400
author Lee, Royce J.
Coccaro, Emil F.
Cremers, Henk
McCarron, Rosemary
Lu, Shi-Fang
Brownstein, Michael J.
Simon, Neal G.
author_facet Lee, Royce J.
Coccaro, Emil F.
Cremers, Henk
McCarron, Rosemary
Lu, Shi-Fang
Brownstein, Michael J.
Simon, Neal G.
author_sort Lee, Royce J.
collection PubMed
description Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist, blocks the effect of intranasally administered vasopressin on brain processing of angry Ekman faces. An interaction of intranasal and oral drug was predicted in the amygdala. Methods: Twenty-nine healthy male subjects received a baseline fMRI scan while they viewed angry faces and then were randomized to receive oral SRX246 (120 mg PO twice a day) or placebo. After an average of 7 days of treatment, they were given an acute dose of intranasal vasopressin (40 IU) or placebo and underwent a second scan. The primary outcome was BOLD activity in the amygdala in response to angry faces. Secondary analyses were focused on ROIs in a brain regions previously linked to vasopressin signaling. Results: In subjects randomized to oral placebo-intranasal vasopressin, there was a significantly diminished amygdala BOLD response from the baseline to post-drug scan compared with oral placebo-intranasal placebo subjects. RM-ANOVA of the BOLD signal changes in the amygdala revealed a significant oral drug × intranasal drug × session interaction (F((1, 25)) = 4.353, p < 0.05). Follow-up tests showed that antagonism of AVPR1a with SRX246 blocked the effect of intranasal vasopressin on the neural response to angry faces. Secondary analyses revealed that SRX246 treatment was associated with significantly attenuated BOLD responses to angry faces in the right temporoparietal junction, precuneus, anterior cingulate, and putamen. Exploratory analyses revealed that the interactive and main effects of intranasal vasopressin and SRX246 were not seen for happy or neutral faces, but were detected for aversive faces (fear + anger) and at a trend level for fear faces. Conclusion: We found confirmatory evidence that SRX246 has effects on the amygdala that counter the effects of intranasal vasopressin. These effects were strongest for angry faces, but may generalize to other emotions with an aversive quality.
format Online
Article
Text
id pubmed-3859978
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38599782013-12-27 A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study Lee, Royce J. Coccaro, Emil F. Cremers, Henk McCarron, Rosemary Lu, Shi-Fang Brownstein, Michael J. Simon, Neal G. Front Syst Neurosci Neuroscience Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist, blocks the effect of intranasally administered vasopressin on brain processing of angry Ekman faces. An interaction of intranasal and oral drug was predicted in the amygdala. Methods: Twenty-nine healthy male subjects received a baseline fMRI scan while they viewed angry faces and then were randomized to receive oral SRX246 (120 mg PO twice a day) or placebo. After an average of 7 days of treatment, they were given an acute dose of intranasal vasopressin (40 IU) or placebo and underwent a second scan. The primary outcome was BOLD activity in the amygdala in response to angry faces. Secondary analyses were focused on ROIs in a brain regions previously linked to vasopressin signaling. Results: In subjects randomized to oral placebo-intranasal vasopressin, there was a significantly diminished amygdala BOLD response from the baseline to post-drug scan compared with oral placebo-intranasal placebo subjects. RM-ANOVA of the BOLD signal changes in the amygdala revealed a significant oral drug × intranasal drug × session interaction (F((1, 25)) = 4.353, p < 0.05). Follow-up tests showed that antagonism of AVPR1a with SRX246 blocked the effect of intranasal vasopressin on the neural response to angry faces. Secondary analyses revealed that SRX246 treatment was associated with significantly attenuated BOLD responses to angry faces in the right temporoparietal junction, precuneus, anterior cingulate, and putamen. Exploratory analyses revealed that the interactive and main effects of intranasal vasopressin and SRX246 were not seen for happy or neutral faces, but were detected for aversive faces (fear + anger) and at a trend level for fear faces. Conclusion: We found confirmatory evidence that SRX246 has effects on the amygdala that counter the effects of intranasal vasopressin. These effects were strongest for angry faces, but may generalize to other emotions with an aversive quality. Frontiers Media S.A. 2013-12-12 /pmc/articles/PMC3859978/ /pubmed/24376401 http://dx.doi.org/10.3389/fnsys.2013.00100 Text en Copyright © 2013 Lee, Coccaro, Cremers, McCarron, Lu, Brownstein and Simon. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lee, Royce J.
Coccaro, Emil F.
Cremers, Henk
McCarron, Rosemary
Lu, Shi-Fang
Brownstein, Michael J.
Simon, Neal G.
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title_full A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title_fullStr A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title_full_unstemmed A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title_short A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
title_sort novel v1a receptor antagonist blocks vasopressin-induced changes in the cns response to emotional stimuli: an fmri study
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859978/
https://www.ncbi.nlm.nih.gov/pubmed/24376401
http://dx.doi.org/10.3389/fnsys.2013.00100
work_keys_str_mv AT leeroycej anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT coccaroemilf anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT cremershenk anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT mccarronrosemary anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT lushifang anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT brownsteinmichaelj anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT simonnealg anovelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT leeroycej novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT coccaroemilf novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT cremershenk novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT mccarronrosemary novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT lushifang novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT brownsteinmichaelj novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy
AT simonnealg novelv1areceptorantagonistblocksvasopressininducedchangesinthecnsresponsetoemotionalstimulianfmristudy